Amgen Completes Acquisition of KAI Pharmaceuticals

Amgen announced the completion of its acquisition of KAI Pharmaceuticals today. The company was acquired for its lead product candidate KAI-4169, which is a novel agent being studied for the treatment of secondary hyperparathyroidism in patients with chron... [more]

View complete Press Release article